Ads
related to: pulmonary adenocarcinoma with lepidic pattern
Search results
Results From The WOW.Com Content Network
Adenocarcinoma in situ (AIS) of the lung —previously included in the category of "bronchioloalveolar carcinoma" (BAC)—is a subtype of lung adenocarcinoma. It tends to arise in the distal bronchioles or alveoli and is defined by a non-invasive growth pattern.
Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. [1] It is classified as one of several non-small cell lung cancers (NSCLC), to distinguish it from small cell lung cancer which has a different behavior and prognosis.
Acinar adenocarcinoma of the lung is a highly lethal disease. Overall, the five-year survival rates approximate 16% to 22%. Generally, survival is better in all stages for patients with the acinar (or papillary) pattern than it is in patients with the solid pattern, but considerably worse than those with the bronchioloalveolar pattern.
Minimally invasive adenocarcinoma of the lung (MIA) is defined as a small (≤3 cm), solitary tumour with predominant alveolar epithelial appearance (lepidic growth), as in situ adenocarcinoma of the lung, with a zone of focal invasion of the stroma with a size inferior to 5 mm. [1] For MIA—as with adenocarcinoma in situ—, the prognosis is near 100% survival.
Lung cancer is the most diagnosed and deadliest cancer worldwide, with 2.2 million cases in 2020 resulting in 1.8 million deaths. [3] Lung cancer is rare in those younger than 40; the average age at diagnosis is 70 years, and the average age at death 72. [2] Incidence and outcomes vary widely across the world, depending on patterns of tobacco use.
Lung cancers are now considered a large and extremely heterogeneous family of neoplasms [4] that feature widely varying genetic, biological, and clinical characteristics. . About 50 different lung cancer variants are recognized under the 2004 revision of the World Health Organization ("WHO-2004") histological typing system, the most widely recognized and used lung cancer classification sche